A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting
Baumeister, A., Cruz, N., Goplan, P., Griffo, A., Israel, A., Kucherer, S., Lightfoot, M., Panny, B., Pizon, A., Price, R., Rengasamy, M., Rohac, R., Shivanekar, S., Spotts, C.
This open-label study (n=16) explores the effects of a single dose of intravenous (IV) ketamine (35mg/70kg) in a real-world sample of participants who had recently attempted suicide. Ketamine led to significant and rapid reductions across all measures, with the largest effect sizes observed up to five days post-infusion. Reductions in suicidality were maintained up to six months after the infusion.
Abstract
Ketamine, in research settings, rapidly reduces suicidal thoughts 2-24 h after a single infusion in patients with high suicidal ideation. In this study, the authors investigate ketamine’s effects on suicidality in a real-world sample of recent suicide attempters on a tertiary-care Consultation-Liaison (CL) psychiatry service. Using an open-label design, 16 transdiagnostic CL patients were recruited, 18-65 years old, to receive a single dose of intravenous ketamine (0.5 mg/kg) in the acute medical setting. All were psychiatrically hospitalized post-infusion. Baseline suicidality and depression measures were compared to ratings taken at 24 h, 5 days, 12 days, and 1, 3 and 6 months post-infusion using paired t-tests. Across all measures, rapid, statistically significant decreases (p’s < 0.001) were observed with large to very large effect sizes (Cohen’s d’s: 1.7-8.8) at acute time points (24 h; 5 days). These gains were uniformly maintained to 6 months post-infusion. Open-label ketamine appeared to rapidly and robustly reduced suicidal symptoms in an ultra-high-risk, heterogeneous, real-world sample. Ketamine infusion may therefore be a safe, feasible, viable method to rapidly reduce suicidality among medically hospitalized patients after a suicide attempt, with potentially enduring benefits. The current pilot findings suggest ketamine could be readily integrated into the settings where high-risk CL patients already receive healthcare, with the potential to become an important and novel tool in the treatment of suicidality.